Loading
Every dated change on the records linked to Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Tumour-agnostic therapies: pembrolizumab or nivolumab for MSI-high or high tumour mutational burden, NTRK inhibitors, BRAF and MEK inhibitors, HER2-directed therapy.
Platinum-based doublet (carboplatin-paclitaxel or gemcitabine-cisplatin) for three cycles, then continuation or a switch to molecularly guided therapy where an actionable alteration is found (CUPISCO).
Best supportive care with early palliative care involvement.
Alternative chemotherapy, PD-1 antibody if not given (nivolumab approved in Japan), or trial entry; trials of antibody-drug conjugates and immunotherapy combinations.
Exclude favourable subsets; comprehensive genomic profiling of tissue or plasma; assess performance status and lactate dehydrogenase.